Drug Repositioning: The Definitive Guide to Rescuing Shelved Assets for Rare, Orphan, and Neglected Diseases
1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost
Insights
PBMs, Formularies, and Rebates: What Investors Should Know
Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
Drug Patent Expiry and Drug Price Erosion: The Definitive Analyst’s Guide to Loss of Exclusivity, Generic Entry, and Biosimilar Market Dynamics
1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows
Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows Read Post »
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation
Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
Pharmaceutical Portfolio Management: The Definitive Technical Guide for IP Teams, R&D Leads, and Institutional Investors
1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of
Follow-On Drug Patents: The IP Strategy Guide That Generic Manufacturers Don’t Want You to Read
How secondary pharmaceutical patents work, why they survive litigation, and what evergreening debates actually get wrong about post-approval R&D economics
India’s Section 3(d): The Definitive IP Strategy Guide for Pharmaceutical and Biotech Companies
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent
U.S. vs. China Pharmaceutical Patent Strategy: The Definitive Analyst’s Guide to IP Valuation, Enforcement, and Competitive Positioning
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
